| 產(chǎn)品編號(hào) | BIO0996SM |
| 英文名稱 | Anti-cMet & EGFR Reference Antibody (Amivantamab Biosimilar) |
| 別 名 | HGFR / c-Met & ERBB1 / EGFR / HER1; Amivantamab |
| 抗體來(lái)源 | |
| 克隆類型 | Monoclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 145.9kDa |
| 性 狀 | Lyophilized |
| 亞 型 | IgG-like |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Co-incubation of Amivantamab with HGF, then with the addition of Human c-MET (Luc) HEK293 Reporter cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Amivantamab was able to block HGF/c-Met signaling pathway, and the IC50 was 0.166 nM.
Amivantamab bound to huMet-HEK293(A3) cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Amivantamab bound to huMet-HEK293(A3) cells, and the EC50 was 0.609 nM.
Amivantamab bound to EGFR-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Amivantamab bound to EGFR-CHO-K cells, and the EC50 was 2.161 nM.
Amivantamab bound to cMet protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Amivantamab bound human cMet Protein-His, and the EC50 was 0.004 nM.
Amivantamab bound to ERBB1/EGFR/HER1 protein, and then rebounded to secondary antibodies(Anti-Human-κ+λ-HRP) , and read OD450. As shown in fig, Amivantamab bound human ERBB1/EGFR/HER1 Protein-Fc, and the EC50 was 0.232 nM.
The purity of Anti-cMet & EGFR Reference Antibody (Amivantamab) is 98.79%, determined by SEC-HPLC.
Anti-cMet & EGFR Reference Antibody (Amivantamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
